euro adhoc: Intercell AG / other / Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

13.06.2008

» Further clinical trial for a seasonal flu vaccine containing
Intercell´s adjuvant IC31® being initiated

» Intercell will be entitled to receive EUR 2 m milestone payment
upon the vaccination of the first human subject in the clinical
trial

Vienna (Austria), June 13, 2008 - Intercell AG (VSE: ICLL) today
announced progress in its collaboration with Novartis to develop an
improved Influenza vaccine. Novartis now has initiated its in-house
development program with clinical trials designed to demonstrate
safety and immunogenicity of a seasonal Influenza vaccine adjuvanted
with IC31®. This triggers a milestone payment of EUR 2 m to
Intercell. As part of the agreement between Novartis and Intercell,
signed in July 2007, Novartis has an exclusive license for
development of Intercell's IC31® adjuvant in novel influenza
vaccines. As announced in February 2008 Intercell completed an
initial Phase I clinical trial of the company's adjuvant IC31® in
combination with the seasonal, trivalent influenza vaccine Agrippal®
from Novartis. The IC31® adjuvanted vaccine showed an excellent
safety and tolerability profile, which was comparable to the
non-adjuvanted standard vaccine. Furthermore in all study groups
vaccination with the test vaccine led to the induction of virus
specific T-cells and protective levels of antibody responses against
the three included influenza strains.

Gerd Zettlmeissl, CEO of Intercell, commented: "Intercell's IC31® has
shown excellent preclinical data and an encouraging profile in first
trials in humans and we are confident that an influenza vaccine
formulated with IC31® now further developed by Novartis has potential
to become a next generation vaccine."

About IC31®

Vaccines, based on antigens alone, are not sufficient to provide full
protection. Adjuvants are needed to educate the immune system to
recognize and eliminate the pathogens efficiently. IC31® is an
adjuvant that induces T-cell and B-cell responses by using a unique
synthetic formulation which combines the immunostimulating properties
of an anti-microbial peptide, KLK, and an immunostimulatory
oligodeoxynucleotide, ODN1a. The two component solution can be simply
mixed with antigens; no conjugation is required. Intercell currently
uses IC31® in collaborations with a number of global vaccine
companies and biotech companies. These collaborations include amongst
others the development of a tuberculosis vaccine in Phase I clinical
trials, which has been partnered with the Danish Statens Serum
Institut and Sanofi Pasteur.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market